Financial results for the first half of 2012

• Three-year cash horizon resulting from collaboration and licensing agreement with Bristol-Myers Squibb
• Significant advance of the IPH21 program with the regulatory authorization to start the first randomized Phase II clinical trial in acute myeloid leukemia

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its financial results for the first half of 2012.

The key elements of Innate Pharma’s financial results for the first half of 2012 are as follows:

• Increase in revenue and other income to 7.7 million euros
• Decrease in net loss amounting to 2.0 million euros
• Cash, cash equivalents and current financial instruments of 37.7 million euros

A meeting for fund managers, financial analysts and journalists
will be held today at 8:30 am (CET) at the SFAF premises in Paris
 24, rue de Penthièvre, 75008
 
 A conference call will be held today at 3:00 pm (CET)
Dial in number: +33 (0)1 70 77 09 41
A replay will be available until December 6, 2012
 Dial in number: +33 (0)1 72 00 15 00
Access number: 278049#